---
category: news
title: "Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé's AI Platform for Drug Design"
excerpt: "Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with"
publishedDateTime: 2022-07-26T07:53:00Z
originalUrl: "https://markets.businessinsider.com/news/stocks/two-clinical-studies-to-treat-mild-to-moderate-covid-19-at-home-reveal-value-of-exscalate-dompé-s-ai-platform-for-drug-design-1031614341"
webUrl: "https://markets.businessinsider.com/news/stocks/two-clinical-studies-to-treat-mild-to-moderate-covid-19-at-home-reveal-value-of-exscalate-dompé-s-ai-platform-for-drug-design-1031614341"
type: article
quality: 41
heat: 41
published: false

provider:
  name: Business Insider
  domain: businessinsider.com
  images:
    - url: "https://everyday-cc.github.io/ai/assets/images/organizations/businessinsider.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - Facebook AI
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1865797/Dompe_Exscalate.jpg"
    width: 400
    height: 226
    isCached: true

secured: "hNNq4C92NAnhD3unFJmeBg8ZFmkSU0zfBnfqLb/bJS5TkKLth6wTvnk7+LgUV5nKOv7T9bMJdIQvuBe4hD/yzAvCC5o7UnzjGfblIZWsJ4FTaWhIsC1FU8SguaA9MCBcjmrc5cJ6lTC13+bZYPn8a9kht02Wq/SeW/vvpirM/pw3gLvWXx0SSGrsf4DpywgPuEi0oYeE/t1Y0beUARG2Jjm8458kDGQQdFtYVXXYWBrXoa+A4I7n4ov7yihhkiYLD+GN1JpezKS7QKw8UILAR92MxsL6QHKsizYR8Rm6UrjlhN2AaDUgN+tNcEyB3mz3Fz67Ng/Rq4STUCLw5Qw54GMS4fGd29gqJNbHOIHS+IM=;MpT9vSEwtLzdbApAb/hdsA=="
---

